Has your child been diagnosed with a primary immunodeficiency disease (PIDD)?

Primary Immunodeficiency is a condition that impairs the immune system and many people with PIDD receive immunoglobulin treatment as a replacement therapy.  The purpose of this study is to evaluate the safety and effectiveness of ASCENIV™, an FDA approved IVIG therapy when given to patients age 2-11 with Primary Immunodeficiency disease.

Study Benefits

• Study participants may experience a reduction in severity and frequency of infections.
• All study-related visits will be provided at no cost
• Study participants will receive $150 for each completed study visit

Study Participant Criteria

• Male or female patients between 2 and 11 years of age.
• Must have a diagnosis of primary immunodeficiency disease.
• Received IGIV therapy maintained at a steady dose for at least 3 months prior to screening

Study Participant Expectations

• Participants will receive up to 7 infusions over a 5-7 month period of time
• Blood and urine samples will be collected at periodic study visits
• Total study participation will be 9 months